Navigation Links
Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
Date:4/4/2019

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it will host a roundtable session at the World Orphan Drug Congress which takes place at the Gaylord National Harbor Hotel, Oxon Hill, Maryland, on April 10-12, 2019.

On Thursday, April 11 at 3:30 p.m., Matthew Mollan, Ph.D., General Manager of Catalent’s Kansas City, Missouri facility and Jim Spavins, retired Senior Vice President of Pharmaceutical Sciences at Pfizer, will discuss orphan drug supply during a roundtable session. Titled “Planning for Orphan Drug Supply: The Importance of Manufacturability”, the roundtable will be moderated by Cornell Stamoran, Ph.D., Catalent’s Vice President of Strategy and Corporate Development and Co-chair of the Catalent Applied Drug Delivery Institute. The session will include a discussion around the accelerated approval pathways that are often associated with orphan drugs in the U.S. and Europe. It will also explore the unique challenges that orphan drugs bring to development, to the clinic, and to scaling up for commercial supply, and discuss the importance of druggability, manufacturability, and patient usage for orphan product success.

Dr. Mollan leads more than 400 colleagues involved in the manufacture and analytical testing of clinical and commercial pharmaceutical products. Prior to joining Catalent, he was Director of Research Formulations at Pfizer. In other roles at Pfizer, he worked in technology development of continuous manufacturing systems, hot melt extrusion, and nanoparticles. Dr. Mollan received a bachelor’s degree in pharmacy and a doctorate in pharmaceutical science, both from Rutgers University, New Brunswick, New Jersey.

Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He has spent nearly 30 years engaged with the health care industry, including more than 25 years in advanced drug and biologic delivery and outsourcing. In 2012, Dr. Stamoran founded the Catalent Applied Drug Delivery Institute, whose mission is to educate and advocate for the enhanced use of drug delivery technologies to improve patient outcomes.

To arrange a meeting with any of the Catalent executives attending the event, contact Richard Kerns at NEPR - richard@nepr.agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/planning_for_orphan_drug_supply_to_be_discussed_by_catalent_at_world_orphan_drug_congress/prweb16210506.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. New book calls for expanded role of indigenous peoples in worldwide conservation planning
2. Research shows impact of soft drinks in meal planning
3. Green planning needed to maintain city buildings
4. Far north at risk unless Ontario adopts new, inclusive planning process: Report
5. Global survey: Climate change now a mainstream part of city planning
6. Planning and building products and production plants simultaneously
7. Population Council to present more than 40 studies at International Conference on Family Planning
8. NSF approves planning grant for Center for Advanced Research in Drying
9. MassBiologics receives orphan drug status from FDA for hepatitis C treatment
10. Resilinc Unveils Streamlined AI Powered EventWatch® as an Entry Level Solution for Supply Chain Risk Management
11. IBM Research and Cornell University to Use Genetic Sequencing and Big Data Analytics to Help Keep Global Milk Supply Safe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2019)... ... July 24, 2019 , ... NDA Partners ... quality assurance expert with more than 20 years of experience working in scientific ... joined the firm as an Expert Consultant. , Dr. Hartzfeld has experience in ...
(Date:7/23/2019)... ... July 23, 2019 , ... NanoFUSE is ... biologic strip indicated for spine and orthopedic use. Bioactive glass is a calcium ... has been clinically-proven in orthopedics for over 30 years and now NanoFUSE Biologics ...
(Date:7/19/2019)... (PRWEB) , ... July 19, 2019 , ... ... Solids between Amorphous and Crystalline States – Insights from Synchrotron X-ray Pair Distribution ... Improved Pharma, along with Chris Benmore of Argonne National Laboratory and Gabriel de ...
Breaking Biology News(10 mins):
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... ... Colorado to focus on prepackaged mobile phases for QC laboratories. After gaining a ... from its laboratory sciences approach into a valued supplier of manufacturing processing solutions, ...
(Date:8/6/2019)... , ... August 06, 2019 , ... ... for characterizing microbiome populations down to the strain level, has announced partnerships with ... and other products to companies and research organizations in Australia, Benelux, Indonesia, Korea, ...
(Date:7/30/2019)... ... July 30, 2019 , ... ... building and cooking events company. Not only has the company already hosted many ... offering Private Cooking Parties to its guests. , With Lajollacooks4u’s Private Cooking Parties, ...
(Date:7/19/2019)... , ... July 18, 2019 , ... ... as “Ravi Everest,” will be joining forces with California-based charity Coalition Duchenne for ... July 20-22nd. Coalition Duchenne raises awareness and funding for Duchenne muscular dystrophy and ...
Breaking Biology Technology: